Mitigating and Managing Ocular Toxicity With Antibody-Drug Conjugate Therapy*

Recommended eye exam schedule to help mitigate ocular toxicity with belantamab mafodotin (belamaf)[1]

- Ophthalmic examinations include visual acuity and slit lamp; perform baseline examinations within 3 weeks prior to the first dose
- Perform each follow-up examination at least 1 week after the previous dose and within 2 weeks prior to the next dose



Advise patients preparing to receive belamaf to[2]:

- Use preservative-free lubricant eye drops at least four times daily, starting with the first infusion until end of treatment
- Recommend AGAINST using corticosteroid eye drops as a prophylactic treatment for microcyst-like epithelial changes
- Avoid use of contact lenses unless directed by an eye care professional
- Use caution when driving or operating machinery, as belamaf may affect vision

For more information on ocular toxicity in belamaf, refer to the prescribing information.

*Belantamab mafodotin was withdrawn from the US market in November 2022. Patients already enrolled in the Risk Evaluation and Mitigation Strategy (REMS) program will have the option to enroll in a compassionate use program to continue to access treatment. No new patients can be enrolled in the REMS as of November 22, 2022. Health care providers can, however, continue to enroll patients in belantamab mafodotin clinical trials.

1. Blenrep (belantamab mafodotin-blmf [belamaf]) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2022.
2. Farooq AV et al. *Ophthalmol Ther.* 2020;9:889.